Study S001657

Investigation of Pharmacokinetics of Two Different Presentations of Cagrilintide in Participants With Overweight and Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07605052
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 50
Start: 2026-05-20
Primary completion: 2026-08-19
Lead sponsor: Novo Nordisk A/S
Conditions: Overweight; Obesity
Interventions: DRUG:Cagrilintide B; DRUG:Cagrilintide D
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1336-5994

Registered primary outcomes

AUCss: area under the total cagrilintide concentration-time curve at steady state after 5th dosing of cagrilintide [From Pre-dose at Day 29 to Day 36]
Cmax,ss: maximum observed concentration of total cagrilintide at steady state after 5th dosing of cagrilintide [From Pre-dose at Day 29 to Day 36]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.